FHTX

Foghorn Therapeutics Inc. (FHTX) | Rumor.io

Foghorn Therapeutics

FHTX

Attention (50-day avg)0%

Attention rank (50-day avg)#3,245

Bullish sentiment (50-day avg)100%

Price to earnings ratio-2.99

Market capitalization209M

Earnings per share-0.99

Dividend yield (TTM)—

Revenue (annual)30.9M

Net income (annual)-74.3M

Social

What share of all stock conversation is about FHTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Jan 12

Foghorn Therapeutics Inc. (FHTX) raised $50 million in equity financing at a 30% premium to the closing stock price on January 9, 2026.
The funds will advance FHTX's R&D pipeline through 2026, including clinical data for FHD-286 and FHD-909, with support from investors BVF, Deerfield, and Flagship Pioneering.
FHTX's stock price has increased by up to 16.8% following the equity financing, with analysts setting a target price of $7.00.

Generated by AI

Sentiment

Of the messages about FHTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	89.58% -5.73
Bearish	—	—	—	10.42% +5.73

Bullish· Feb 9

Foghorn Therapeutics Inc. (FHTX) has a strong partnership with Eli Lilly, with an upfront payment of $300 million and additional potential milestone payments.
The company has a promising product pipeline, with multiple targets and a unique technology that has shown potential in early-stage clinical trials.
FHTX has significant growth potential, with a target price of $8 or $12 per share and the possibility of a buyout, making it a solid long-term investment opportunity.

Bearish· Dec 13

$FHTX is experiencing a significant after-hours drop, setting the stage for an epic decline.
The company's 50% spike is attributed to paid promotions and vague promises, rather than actual value, raising concerns about its legitimacy.
$FHTX's price is vulnerable to a major crash, potentially dropping to the 10-13 range, making it a high-risk investment.

Generated by AI

Topics

Of the messages about FHTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	82.76%
Analysts	—	—	—	3.45%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	13.79%

Announcements· Dec 16

Foghorn Therapeutics Inc. ($FHTX) has discontinued the development of its clinical-stage candidate FHD-286 in acute myeloid leukemia (AML) due to the drug's failure to meet the efficacy threshold in a phase 1 study.
The company will prioritize investment in its proprietary pipeline and collaboration programs, including a clinical-stage selective SMARCA2 (BRM) inhibitor, FHD-909, and has $267M in cash, providing a cash runway into 2027.
Foghorn Therapeutics is evaluating partnerships and investigator-sponsored trials (ISTs) to advance the development of FHD-286, and has halted the independent development of the drug in combination with decitabine for treating relapsed and/or refractory AML.

Technical Analysis· Dec 13

$FHTX broke downtrend and needs to break $17.6-$17.7 area for further gains.
$FHTX RSI is 71%, indicating a potential reversal to 21.69.
$FHTX is setting up a bull flag and Cup n Handle pattern, with a potential run to 20+ and all-time high area of 28.

Generated by AI

Community

Of the messages about FHTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	85.71%	16.48%
Newcomers	100%	100%	14.29%	83.52%

Regulars· Apr 24

Foghorn Therapeutics Inc. has paused enrollment in the FHD-609 study due to a grade 4 QTc prolongation event in a patient at the second highest dose.
The company has filed a Form 8-K with the SEC, providing an update on the FHD-609 study and its progress.
Foghorn Therapeutics Inc.'s quarterly revenue growth rate YoY is 16080.50%, ranking 18 out of 5751 companies in the database.

Newcomers· Aug 23

The FDA has placed a full hold on Foghorn's phase 1 trial due to suspected patient deaths, which may impact the company's progress.
New investors are considering $FHTX as a potential rebound stock, despite the day's performance being negative.
Foghorn Therapeutics has provided an update on its phase 1 study for FHD-286 in relapsed/refractory AML/MDS, which may be relevant to clinical trial enthusiasts.

Generated by AI

News

Citizens reiterates Foghorn Therapeutics stock rating on trial data

13d agoInvesting.com

B. Riley Securities Initiates a Buy Rating on Foghorn Therapeutics (FHTX)

Detailed price information for Foghorn Therapeutics Inc (FHTX-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 67.01%: Read This Before Placing a Bet

The consensus price target hints at a 67% upside potential for Foghorn Therapeutics (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

1mo agoYahoo Finance

Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12

1mo agoInvesting.com

Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy

1mo agoYahoo Finance

Evercore ISI Reaffirms Their Buy Rating on Foghorn Therapeutics (FHTX)

Detailed price information for Foghorn Therapeutics Inc (FHTX-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about FHTX also mention

#	Name	Attention
1	Kymera Therapeutics Inc.KYMR	0%0
2	Immunocore Holdings plc ADRIMCR	0%0
3	Bicycle Therapeutics plc - ADRBCYC	0%0
4	Nkarta, Inc.NKTX	0%0
5	Fulcrum Therapeutics, Inc.FULC	0%0
6	Wave Life Sciences Ltd.WVE	0%+0
7	SWTX - SpringWorks Therapeutics, Inc.	——
8	4D Molecular Therapeutics, Inc.FDMT	0%new
9	Seres Therapeutics Inc.MCRB	0%0
10	Arvinas, Inc.ARVN	0%+0

Foghorn Therapeutics Inc.

Healthcare
Biotechnology

Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines that correct abnormal gene expression. Foghorn Therapeutics Inc. uses its proprietary Gene Traffic Control platform to study the chromatin regulatory system, a core mechanism that influences how genes are activated or silenced in cells. Its current programs are centered on oncology, with efforts directed at genetically defined cancers and other serious diseases linked to chromatin-driven dependencies. The company’s research and development activities include precision therapeutics designed to identify and validate drug targets within this regulatory network, supporting the creation of targeted treatments for hard-to-address diseases. Headquartered in Watertown, Massachusetts, Foghorn Therapeutics Inc. plays a specialized role in the biotechnology market as a developer of novel, mechanism-based therapies.

Website

Location

99 Coolidge Avenue

Watertown, MA, 02472

United States

Social

What share of all stock conversation is about FHTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Jan 12

Foghorn Therapeutics Inc. (FHTX) raised $50 million in equity financing at a 30% premium to the closing stock price on January 9, 2026.
The funds will advance FHTX's R&D pipeline through 2026, including clinical data for FHD-286 and FHD-909, with support from investors BVF, Deerfield, and Flagship Pioneering.
FHTX's stock price has increased by up to 16.8% following the equity financing, with analysts setting a target price of $7.00.

Generated by AI

Sentiment

Of the messages about FHTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	89.58% -5.73
Bearish	—	—	—	10.42% +5.73

Bullish· Feb 9

Foghorn Therapeutics Inc. (FHTX) has a strong partnership with Eli Lilly, with an upfront payment of $300 million and additional potential milestone payments.
The company has a promising product pipeline, with multiple targets and a unique technology that has shown potential in early-stage clinical trials.
FHTX has significant growth potential, with a target price of $8 or $12 per share and the possibility of a buyout, making it a solid long-term investment opportunity.

Bearish· Dec 13

$FHTX is experiencing a significant after-hours drop, setting the stage for an epic decline.
The company's 50% spike is attributed to paid promotions and vague promises, rather than actual value, raising concerns about its legitimacy.
$FHTX's price is vulnerable to a major crash, potentially dropping to the 10-13 range, making it a high-risk investment.

Generated by AI

Topics

Of the messages about FHTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	82.76%
Analysts	—	—	—	3.45%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	13.79%

Announcements· Dec 16

Foghorn Therapeutics Inc. ($FHTX) has discontinued the development of its clinical-stage candidate FHD-286 in acute myeloid leukemia (AML) due to the drug's failure to meet the efficacy threshold in a phase 1 study.
The company will prioritize investment in its proprietary pipeline and collaboration programs, including a clinical-stage selective SMARCA2 (BRM) inhibitor, FHD-909, and has $267M in cash, providing a cash runway into 2027.
Foghorn Therapeutics is evaluating partnerships and investigator-sponsored trials (ISTs) to advance the development of FHD-286, and has halted the independent development of the drug in combination with decitabine for treating relapsed and/or refractory AML.

Technical Analysis· Dec 13

$FHTX broke downtrend and needs to break $17.6-$17.7 area for further gains.
$FHTX RSI is 71%, indicating a potential reversal to 21.69.
$FHTX is setting up a bull flag and Cup n Handle pattern, with a potential run to 20+ and all-time high area of 28.

Generated by AI

Community

Of the messages about FHTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	85.71%	16.48%
Newcomers	100%	100%	14.29%	83.52%

Regulars· Apr 24

Foghorn Therapeutics Inc. has paused enrollment in the FHD-609 study due to a grade 4 QTc prolongation event in a patient at the second highest dose.
The company has filed a Form 8-K with the SEC, providing an update on the FHD-609 study and its progress.
Foghorn Therapeutics Inc.'s quarterly revenue growth rate YoY is 16080.50%, ranking 18 out of 5751 companies in the database.

Newcomers· Aug 23

The FDA has placed a full hold on Foghorn's phase 1 trial due to suspected patient deaths, which may impact the company's progress.
New investors are considering $FHTX as a potential rebound stock, despite the day's performance being negative.
Foghorn Therapeutics has provided an update on its phase 1 study for FHD-286 in relapsed/refractory AML/MDS, which may be relevant to clinical trial enthusiasts.

Generated by AI

Foghorn Therapeutics

Social

Jan 12

Bullish· Feb 9

Bearish· Dec 13

Announcements· Dec 16

Technical Analysis· Dec 13

Regulars· Apr 24

Newcomers· Aug 23

Citizens reiterates Foghorn Therapeutics stock rating on trial data

B. Riley Securities Initiates a Buy Rating on Foghorn Therapeutics (FHTX)

Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 67.01%: Read This Before Placing a Bet

Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12

Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy

Evercore ISI Reaffirms Their Buy Rating on Foghorn Therapeutics (FHTX)

Also Discussed

Foghorn Therapeutics Inc.

Company Information

Location

Citizens reiterates Foghorn Therapeutics stock rating on trial data

B. Riley Securities Initiates a Buy Rating on Foghorn Therapeutics (FHTX)

Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 67.01%: Read This Before Placing a Bet

Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12

Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy

Evercore ISI Reaffirms Their Buy Rating on Foghorn Therapeutics (FHTX)

Also Discussed

Social

Jan 12

Bullish· Feb 9

Bearish· Dec 13

Announcements· Dec 16

Technical Analysis· Dec 13

Regulars· Apr 24

Newcomers· Aug 23